University of Illinois at Chicago researchers have identified new sites on the bacterial cell's protein-making machinery where antibiotics can be delivered to treat infections.
"The primary challenge of antibiotic therapy has been fighting infections caused by the pathogens which became resistant to antibiotics," says Alexander Mankin, professor and associate director of UIC's Center for Pharmaceutical Biotechnology and lead investigator of the study. "Not a single class of drugs has escaped the inevitable emergence of resistance."
At present, Mankin said, "the constant development of new drugs is the only available strategy to keep up with the ever-growing variety of antibiotic-resistant pathogens."
Mankin and his research team are looking for new vulnerable sites on bacteria where drugs can be delivered to fight the infections.
"First we need to find the target, and then the weapons can be developed," he said.
In the study, which is published in the Journal of Biological Chemistry, UIC researchers divided a ribosome -- the main apparatus within the cell that makes protein, and one of the best antibiotic targets -- into specific sections. Random genetic mutations were engineered in each area, and the researchers looked for those alterations that stopped the ribosome from making proteins.
Of the thousands of mutations tested, 77 were detrimental to the function of the ribosome. The regions where those mutations lie can be targeted by new antibiotics, which may be used to treat such diseases as tuberculosis and pneumonia, Mankin said.
"If we find drugs that can bind to these regions, they will likely kill the pathogenic cell," he said.
According to Mankin, the development of microbial genomics brought new hope for the development of antibiotics, but few successful drug candidates have been produced using this method.
An alternative approach is to "follow the lead of nature, and develop new drugs that act on the targets in the course of evolution."
"The ribosome is the perfect target," he said. "More than half of all known antibiotics arrest cell growth by interfering with the ribosomal functions and inhibiting protein synthesis. This is an innovative concept, targeting new sites in the ribosome."
Source: University of Illinois at Chicago
Related stories:
Scientists discover how some bacteria survive antibiotics
Researchers at the University of Illinois at Chicago have discovered how some bacteria can survive antibiotic treatment by turning on resistance mechanisms when exposed to the drugs. The findings, published in the April 24 issue of the journal
Molecular Cell, could lead to more effective antibiotics to treat a variety of infections.
Hairpins for switches
How does an organism know when it must produce a protein and in what amount? Clever control mechanisms are responsible for the regulation of protein biosynthesis. One such type of mechanism, discovered only a few years ago, is riboswitches, which function as a sort of "off" switch for the production of certain proteins.
Hairpins for Switches: Artificial RNA ligands differentiate between on and off states of riboswitches
How does an organism know when it must produce a protein and in what amount? Clever control mechanisms are responsible for the regulation of protein biosynthesis. One such type of mechanism, discovered only a few years ago, is riboswitches, which function as a sort of “off” switch for the production of certain proteins. These could be a useful point of attack for novel antibiotics if it were possible to find drugs that bind to the switches of pathogens and “turn off” the biosynthesis of essential proteins in bacteria or fungi.
Biologists probe the machinery of cellular protein factories
Proteins of all sizes and shapes do most of the work in living cells, and the DNA sequences in genes spell out the instructions for making those proteins. The crucial job of reading the genetic instructions and synthesizing the specified proteins is carried out by ribosomes, tiny protein factories humming away inside the cells of all living things.
Nano World: Nanotubes may unfold proteins
Bottling proteins in nanotubes may cause them to unfold, which may drive researchers exploring nanotubes as drug-delivery vehicles to rethink their strategies, experts told UPI's Nano World.
Nanotechnology boosts war on superbugs
This week
Nature Nanotechnology journal (October 12th) reveals how scientists from the London Centre for Nanotechnology (LCN) at UCL are using a novel nanomechanical approach to investigate the workings of vancomycin, one of the few antibiotics that can be used to combat increasingly resistant infections such as MRSA. The researchers, led by Dr Rachel McKendry and Professor Gabriel Aeppli, developed ultra-sensitive probes capable of providing new insight into how antibiotics work, paving the way for the development of more effective new drugs.
Evolution of virulence regulation in Staphylococcus aureus
Scientists have gained insight into the complex mechanisms that control bacterial pathogenesis and, as a result, have developed new theories about how independent mechanisms may have become intertwined during evolution. The research, published by Cell Press in the October 10th issue of the journal
Molecular Cell, may lead to strategies for developing more effective therapeutics against the human pathogen responsible for most of the antibiotic-resistant infections contracted in the community.
Protection for stressed-out bacteria identified
An international team of researchers is a step closer to understanding the spread of deadly diseases such as listeriosis, after observing for the first time how bacteria respond to stress.